Find a Startup

Impacting society, creating change

Technologies developed at Ohio State are changing the world. Learn more about the startups that are a part of the Ohio State portfolio as of June 30, 2021, below. 

Search for a Startup below

Categories Filter
  • All
  • Advanced Materials
  • Agriculture, Food Science & Nutrition
  • Animal Health
  • Electronics, Communications & Networking
  • Energy & Environment
  • Health & Wellness
  • Healthcare IT
  • Medical Devices, Diagnostics & Imaging
  • Research Tools & Reagents
  • Robotics, Sensors & Advanced Manufacturing
  • Software & Information Technology
  • Therapeutics, Drug Delivery & Biotechnology
Showing 36-40 of 105 results
Entrada Therapeutics Inc.
Therapeutics, Drug Delivery & Biotechnology

Entrada Therapeutics is developing an intracellular biologics and drug delivery platform designed to enable new treatments for devastating diseases. Entrada’s delivery vehicles boast improved bioavailability, biodistribution, metabolic stability and enhanced efficiency compared to previous gold standards. Initially the company will focus on utilizing its intracellular delivery system for treating a rare, fatal mitochondria disease with no currently approved treatment options.

College of Arts & Sciences
License Fiscal Year: 2019
Inventor(s): Dehua Pei
CEO: Dipal Doshi
CytoImmune Therapeutics, LLC
Therapeutics, Drug Delivery & Biotechnology

CytoImmune Therapeutics is commercializing a coordinated immunotherapy platform for cancer treatments that combines chimeric antigen receptors (CARs) and bispecific antibodies (biAbs) with T cells and natural killer cells. This technology reduces the patient’s time to personalized treatment and enables optimized dosing with limited off-target effects. The company is developing product candidates targeted at treating acute myeloid leukemia, glioblastoma and multiple myeloma.

College of Medicine
License Fiscal Year: 2019
Inventor(s): Michael Caligiuri
CEO: Will Rosellini
Celenex Inc.
Therapeutics, Drug Delivery & Biotechnology

Celenex is a clinical-stage gene therapy company bringing to market a portfolio of ten gene therapies licensed from Nationwide Children’s Hospital and The Ohio State University for treatments for lysosomal storage disorders. The company is initially targeting Batten disease, with therapies targeting CLN6, CLN3 and CLN8, as potential first-to-market curative therapies for these rare and devastating diseases. Celenex was acquired by Amicus Therapeutics in September 2018. 

College of Medicine
License Fiscal Year: 2018
Inventor(s): Arthur Burghes
CEO: Samit Varma
Novartis Gene Therapies
Therapeutics, Drug Delivery & Biotechnology

Avexis, now doing business as Novartis Gene Therapies is a biotechnology company developing gene therapies designed to treat rare and life-threatening neurological genetic diseases. The initial proprietary investigational gene replacement therapy, AVXS-101 (onasemnogene abeparvovec-xioi) is in development for the treatment of spinal muscular atrophy (SMA). In addition, the company is pursuing gene therapies for Rett syndrome (AVXS-201) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene (AVXS-301).

College of Medicine
License Fiscal Year: 2014
Inventor(s): Arthur Burghes
CEO: Sean Nolan
Aether Therapeutics Inc.
Therapeutics, Drug Delivery & Biotechnology

Aether Therapeutics develops new therapies for pain and addiction. The company is developing its lead compound, 6BMX, as a first-in-class treatment strategy for the prevention of neonatal abstinence syndrome (NAS). NAS affects infants born to mothers suffering from opioid addiction, a significantly increasing problem due to the opioid epidemic.

College of Medicine
License Fiscal Year: 2018
Inventor(s): Wolfgang Sadee; John Oberdick
CEO: Brian Cummings